TrialInternational journal of hematology2021

Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial.

Kenshi Suzuki et al.PubMed ↗Publisher ↗

No numbers read from the abstract.